Evidence map›Paper›PMID 33933667›Full record

ArticleContemporary clinical trials2021

Evaluation of an integrated treatment to address smoking cessation and anxiety/depressive symptoms among people living with HIV: Study protocol for a randomized controlled trial.

Lorra Garey, Megan R Wirtz, Allison K Labbe, Michael J Zvolensky, Jasper A J Smits, Thomas P Giordano, David Rosenfield, Gregory K Robbins, Douglas E Levy, Samantha M McKetchnie and 2 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Interventions for tobacco use cessation in people living with HIV.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Article
  3. Tobacco Use and Treatment of Tobacco Dependence Among People With Human Immunodeficiency Virus: A Practical Guide for Clinicians.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Lorra GareyDepartment of Psychology, University of Houston, Houston, TX, United States of America.
Megan R WirtzDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America.
Allison K LabbeDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America.
Michael J ZvolenskyDepartment of Psychology, University of Houston, Houston, TX, United States of America.
Jasper A J SmitsDepartment of Psychology, University of Texas at Austin, Austin, TX, United States of America.
Thomas P GiordanoDepartment of Medicine, Baylor College of Medicine, Houston, TX, United States of America; Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States of America.
David RosenfieldDepartment of Psychology, Southern Methodist University, Dallas, TX, United States of America.
Gregory K RobbinsDepartment of Psychiatry, Harvard Medical School, Boston, MA, United States of America; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States of America.
Douglas E LevyMongan Institute Health Policy Research Center, Massachusetts General Hospital, Boston, MA, United States of America; Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America.
Samantha M McKetchnieDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America; The Fenway Institute, Fenway Health, Boston, MA, United States of America.
Tanisha BellDepartment of Medicine, Baylor College of Medicine, Houston, TX, United States of America.
Conall O'CleirighDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America; The Fenway Institute, Fenway Health, Boston, MA, United States of America. Electronic address: cocleirigh@mgh.harvard.edu.
Massachusetts General Hospital · USFenway Health · USUniversity of Houston · USBaylor College of Medicine · USCenter for Innovation · USHarvard University · USSouthern Methodist University · USThe University of Texas at Austin · US

Funding

Effectivenss of an Integrated Treatment to Address Smoking Cessation and Anxiety/Depression in People Living with HIVR01DA047933 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI O'CLEIRIGH, CONALL MICHAEL, SMITS, JASPER · 2019 to 2023
$4.8M
NIDA NIH HHS R01 DA047933
6 · The paper itself

Abstract

backgroundInterventions that target anxiety/depressive symptoms in the context of smoking treatment have shown promise irrespective of psychiatric diagnosis. Yet, these tailored treatments are largely absent for persons who smoke and are living with HIV (SLWH).

objectiveTo evaluate a novel, smoking cessation intervention that addresses anxiety/depression and HIV-related health (QUIT) against a time-matched control (TMC) and a standard of care (SOC) condition.

methodsSLWH (N = 180) will be recruited and enrolled from 3 medical clinics in Boston, MA, and Houston, TX. The trial will consist of a baseline assessment, a 10-week intervention/assessment period, and follow-up assessments, accounting for a total study duration of approximately 8 months. All participants will complete a baseline visit and a pre-randomization standardized psychoeducation visit, and will then be randomized to one of three conditions: QUIT, TMC, or SOC. QUIT and TMC will consist of nine 60-min, cognitive behavioral therapy-based, individual weekly counseling sessions using standard smoking cessation counseling; additionally, QUIT will target anxiety and depressive symptoms by addressing underlying mechanisms related to mood and quit difficulty. SOC participants will complete weekly self-report surveys for nine weeks. All participants will be encouraged to quit at Session 7 and will be offered nicotine replacement therapy to help.

conclusionsQUIT is designed to improve smoking cessation in SLWH by addressing anxiety and depression and HIV-related health issues. If successful, the QUIT intervention would be ready for implementation and dissemination into "real-world" behavioral health and social service settings consistent with the four objectives outlined in NIDA's Strategic Plan.

Indexed as

HIV InfectionsSmoking CessationAnxietyDepressionHumansRandomized Controlled Trials as TopicTobacco Use Cessation DevicesAnxietyDepressionEfficacy/effectivenessHIVPsychosocial treatmentSmoking cessation

Identifiers

PMID33933667
PMCPMC10080995
OpenAlexW3159036837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.